0.10p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Solvonis Therapeutics
Its shares trade on LSE under the ticker SVNS.L. It has been listed since 6 January 2022. In the fiscal year to 31 December 2023, it reported revenue of £587,000 and a net loss of £3.1m. At that date it held total assets of £2.4m and shareholders' equity of £2.0m.
Graft Polymer (UK) Ltd. is a holding company, which engages in the development and production of polymer. The firm offers bespoke, adapted, and tailored products for customer requests. Its products pipeline includes GRAFTABOND, GRAFTAPOR, GRAFTALEN, GRAFTAKIT, GRAFTALLOY, GRAFTAMID, GRAFTASYNT and GRAFTAMER. GRAFTABOND product is a graft / block copolymers (adhesion promotors) for combining various polymers (with fiberglass, carbon fiber, mineral and natural fillers, mixed polymer waste. The GRAFTAPOR product is a porous polymer carriers for many liquid chemicals. Its GRAFTALEN is a reactive solid super concentrates for polyolefin rheology modification, e-modulus enhancer, polybutylene terephthalate chain extender, AOX masterbatch. GRAFTAKIT is a reactive liquid or solid super concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 6 Jan 2022
- Website
- graftpolymer.com ↗
Leadership
Pay as last reported
- Mr. Dennis PurcellNon-Executive Chairman of the Board£13,000
- Mr. Anthony TennysonChief Executive Officer, Executive Director, since 2024£54,000
- Mr. Ryan NeatesChief Financial Officer
- Prof. David NuttChief Scientific Officer
- Mr. Nicholas NelsonNon-Executive Director£29,000
- Dr. Renata CromeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Graft Polymer (UK) Ltd. develops bespoke polymers for customer requests with products like GRAFTABOND and GRAFTAPOR.
- The product pipeline includes GRAFTALEN for polyolefin rheology modification and GRAFTAMID for reactive solid super concentrates.
- GRAFTAKIT offers reactive liquid or solid super concentrates on polymeric porous media for reaction extrusion.
Weaknesses
- The company operates as a holding company without specified manufacturing facilities in the facts.
- No mention of production capacity or scalability for GRAFTABOND and GRAFTAPOR products.
- Limited information on market share or customer base for GRAFTALEN and GRAFTAMID.
Opportunities
- Expanding GRAFTABOND use in fiberglass and carbon fiber applications could increase market reach.
- GRAFTAPOR's porous polymer carriers may attract chemical industry demand for liquid chemical storage.
- GRAFTAMER could leverage growing demand for sustainable polymer waste solutions.
Threats
- Competition from established chemical companies in polymer production is not addressed in the facts.
- No data on regulatory changes affecting polymer manufacturing in the UK.
- Potential supply chain disruptions for raw materials used in GRAFTALEN production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.